» Articles » PMID: 20667820

Smad2 Positively Regulates the Generation of Th17 Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2010 Jul 30
PMID 20667820
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Development of Foxp3(+) regulatory T cells and pro-inflammatory Th17 cells from naive CD4(+) T cells requires transforming growth factor-β (TGF-β) signaling. Although Smad4 and Smad3 have been previously shown to regulate Treg cell induction by TGF-β, they are not required in the development of Th17 cells. Thus, how TGF-β regulates Th17 cell differentiation remains unclear. In this study, we found that TGF-β-induced Foxp3 expression was significantly reduced in the absence of Smad2. More importantly, Smad2 deficiency led to reduced Th17 differentiation in vitro and in vivo. In the experimental autoimmune encephalomyelitis model, Smad2 deficiency in T cells significantly ameliorated disease severity and reduced generation of Th17 cells. Furthermore, we found that Smad2 associated with retinoid acid receptor-related orphan receptor-γt (RORγt) and enhanced RORγt-induced Th17 cell generation. These results demonstrate that Smad2 positively regulates the generation of inflammatory Th17 cells.

Citing Articles

TRPM7 activity drives human CD4 T-cell activation and differentiation in a magnesium dependent manner.

Hoelting K, Madlmayr A, Hoeger B, Lewitz D, Weng M, Haider T bioRxiv. 2024; .

PMID: 39677770 PMC: 11643021. DOI: 10.1101/2024.12.04.626765.


Targeted therapies in hepatocellular carcinoma: past, present, and future.

Gujarathi R, Franses J, Pillai A, Liao C Front Oncol. 2024; 14:1432423.

PMID: 39267840 PMC: 11390354. DOI: 10.3389/fonc.2024.1432423.


Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.

Danielpour D Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675493 PMC: 11054419. DOI: 10.3390/ph17040533.


TGF-β Signaling in Progression of Oral Cancer.

Guo Y, Xu T, Chai Y, Chen F Int J Mol Sci. 2023; 24(12).

PMID: 37373414 PMC: 10299206. DOI: 10.3390/ijms241210263.


T cells in health and disease.

Sun L, Su Y, Jiao A, Wang X, Zhang B Signal Transduct Target Ther. 2023; 8(1):235.

PMID: 37332039 PMC: 10277291. DOI: 10.1038/s41392-023-01471-y.


References
1.
Yang X, Nurieva R, Martinez G, Kang H, Chung Y, Pappu B . Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008; 29(1):44-56. PMC: 2630532. DOI: 10.1016/j.immuni.2008.05.007. View

2.
Dai F, Lin X, Chang C, Feng X . Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-beta signaling. Dev Cell. 2009; 16(3):345-57. PMC: 2676691. DOI: 10.1016/j.devcel.2009.01.022. View

3.
Deftos M, He Y, Ojala E, Bevan M . Correlating notch signaling with thymocyte maturation. Immunity. 1999; 9(6):777-86. PMC: 2789684. DOI: 10.1016/s1074-7613(00)80643-3. View

4.
Dennler S, Itoh S, Vivien D, Ten Dijke P, Huet S, Gauthier J . Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998; 17(11):3091-100. PMC: 1170648. DOI: 10.1093/emboj/17.11.3091. View

5.
Okamoto K, Iwai Y, Oh-Hora M, Yamamoto M, Morio T, Aoki K . IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature. 2010; 464(7293):1381-5. DOI: 10.1038/nature08922. View